On April 16, 2020, Dr. Ralf Rosskamp, MD, Chief Medical Officer of Dicerna Pharmaceuticals, Inc. announced his intention to retire. In order to facilitate an orderly transition of his duties, the Company entered into a transition and separation agreement with Dr. Rosskamp, executed and effective on April 16, 2020. Pursuant to the Agreement, Dr. Rosskamp will continue as Chief Medical Officer of the Company from the Effective Date through the recruitment and an onboarding transition period of a new Chief Medical Officer. The Agreement further provides that once the Transition Period is complete, Dr. Rosskamp will provide consulting services through at least June 30, 2021 (the “Consulting Period”). The Company has retained Dr. Rosskamp’s service with the goal of continuing his activities in respect of the planned New Drug Application for the Company’s nedosiran program through the filing of the NDA with the U.S. Food and Drug Administration.